title: Axitinib-induced acute pancreatitis: a case report.
abstract: Axitinib is an oral second-generation selective inhibitor of vascular endothelial growth factor receptors recently approved for the treatment of advanced renal cell carcinoma. Numerous cases of acute pancreatitis have been reported after treatment with nonselective tyrosine kinase inhibitors such as sorafenib and sunitinib. We present the first report of a patient under axitinib treatment presenting with acute pancreatitis for which no other etiology has been found. The patient was a 29-year-old woman treated for renal cell carcinoma. The patient had no history of chronic illness, gallstone-related disease, or alcohol consumption. She had been previously treated with sunitinib and everolimus. Four months after the onset of axitinib treatment she was hospitalized for acute pancreatitis. Symptoms and blood lipase levels normalized within a few days after axitinib was withheld. We believe that acute pancreatitis should be recognized as a potential axitinib-related adverse event.
authors.affiliation: Departments of aOncology and Internal Medicine bDigestive Diseases cRadiology, Desgenettes Hospital, University of Lyon, Lyon, France.
authors.forename: Julien
authors.initials: J
authors.lastname: Péron
authors.forename: Safia
authors.initials: S
authors.lastname: Khenifer
authors.forename: Valérie
authors.initials: V
authors.lastname: Potier
authors.forename: Thierry
authors.initials: T
authors.lastname: Vitry
authors.forename: Florian
authors.initials: F
authors.lastname: Pasquet
authors.forename: Robin
authors.initials: R
authors.lastname: Rassat
authors.forename: Michel
authors.initials: M
authors.lastname: Pavic
mesh_terms: D000208:Acute Disease; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077784:Axitinib; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D007191:Indazoles / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy*; D010195:Pancreatitis / Q000139:chemically induced*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D000077784:Axitinib